<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(15)</volume><submitter>Yuan S</submitter><pubmed_abstract>&lt;b>Background:&lt;/b> Liver fibrosis, characterized by excessive extracellular matrix deposition, is a precursor to cirrhosis and hepatocellular carcinoma, and current treatments are often limited by off-target toxicities. &lt;b>Methods and results:&lt;/b> We repurposed the liver-targeting chimera (LIVTAC) XZ1606, a novel proteolysis-targeting chimera (PROTAC) conjugated with a triantennary &lt;i>N&lt;/i>-acetylgalactosamine (tri-GalNAc) moiety, to degrade BRD4 in hepatic stellate cells. &lt;i>In vitro&lt;/i>, XZ1606 induced potent, dose- and time-dependent BRD4 degradation in LX-2 cells via the ubiquitin-proteasomal pathway after ASGPR-mediated endocytosis, with minimal cytotoxicity in normal hepatocytes. TGF-β-activated LX-2 cells exhibited significant reductions in fibrotic markers upon treatment, correlati</pubmed_abstract><journal>Theranostics</journal><pagination>7270-7290</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12315693</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Liver-targeted degradation of BRD4 reverses hepatic fibrosis and enhances metabolism in murine models.</pubmed_title><pmcid>PMC12315693</pmcid><pubmed_authors>Yuan S</pubmed_authors><pubmed_authors>Pan Y</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>He Y</pubmed_authors><pubmed_authors>Dong X</pubmed_authors><pubmed_authors>Guo Y</pubmed_authors><pubmed_authors>Zi M</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Chen C</pubmed_authors><pubmed_authors>Nisar A</pubmed_authors><pubmed_authors>Khan S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Liver-targeted degradation of BRD4 reverses hepatic fibrosis and enhances metabolism in murine models.</name><description>&lt;b>Background:&lt;/b> Liver fibrosis, characterized by excessive extracellular matrix deposition, is a precursor to cirrhosis and hepatocellular carcinoma, and current treatments are often limited by off-target toxicities. &lt;b>Methods and results:&lt;/b> We repurposed the liver-targeting chimera (LIVTAC) XZ1606, a novel proteolysis-targeting chimera (PROTAC) conjugated with a triantennary &lt;i>N&lt;/i>-acetylgalactosamine (tri-GalNAc) moiety, to degrade BRD4 in hepatic stellate cells. &lt;i>In vitro&lt;/i>, XZ1606 induced potent, dose- and time-dependent BRD4 degradation in LX-2 cells via the ubiquitin-proteasomal pathway after ASGPR-mediated endocytosis, with minimal cytotoxicity in normal hepatocytes. TGF-β-activated LX-2 cells exhibited significant reductions in fibrotic markers upon treatment, correlati</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2025-08-27T03:07:03.125Z</modification><creation>2025-08-27T03:07:03.125Z</creation></dates><accession>S-EPMC12315693</accession><cross_references><pubmed>40756370</pubmed><doi>10.7150/thno.113852</doi></cross_references></HashMap>